Timing of Initiation of First-line Antiretroviral Therapy

  • Authors: Marshall J. Glesby, MD, PhD; Timothy J. Wilkin, MD, MPH (More Info)
  • Section Editor: Joel E. Gallant, MD, MPH
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/1/16 (What's New)

Summary

  • Data suggest that uncontrolled HIV replication and advanced HIV disease may contribute to atherosclerosis
    • In the SMART study, there were more coronary heart disease events in patients receiving intermittent ART vs patients receiving continuous therapy[SMART 2006]
    • Potential mechanisms include increased inflammation or worsened lipid profile during treatment interruption[Phillips 2008; Kuller 2008]

Action required

Keywords: Cardiovascular Disease, Initial Antiretroviral Therapy, Pregnancy, Renal Complications, Special Populations, Viral Hepatitis Coinfection

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.